Can the new Pfizer bivalent product represented by code 91317 be used as the first and second dose of the primary series for pediatric patients aged 6 months through 4 years? ...
Subscribe or sign in to view the full article.
Article Overview
This premium article explains current guidance for reporting a pediatric COVID-19 vaccine product and associated vaccine administration codes, with reference to CDC vaccine selection resources. It is intended for coders, billers, and compliance staff who need to confirm whether the article’s coding guidance applies to pediatric primary-series vaccination scenarios.
Why This Topic Matters
Correct vaccine coding depends on pairing the appropriate product and administration codes under current guidance. This article helps reduce reporting errors for pediatric COVID-19 vaccination claims and supports alignment with CDC-directed reporting conventions.
What You Will Learn
- The scope of current reporting guidance for a pediatric COVID-19 vaccine product
- How the article frames the relationship between vaccine product reporting and administration coding
- Where the guidance points readers for CDC vaccine selection information
- Which pediatric primary-series vaccination scenarios are addressed at a high level
Who Should Read This
- Medical coders
- Billing staff
- Compliance professionals
- Pediatric practice staff
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com